Recurrent Breast Cancer Terminated Phase 2 Trials for Lapatinib (DB01259)

Also known as: Breast Cancer Recurrent / Breast cancer NOS recurrent / Carcinoma breast recurrent / Breast carcinoma recurrent / Breast carcinoma NOS recurrent

IndicationStatusPhase
DBCOND0028640 (Recurrent Breast Cancer)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01868503Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast CancerTreatment